Double Medical(SZ:002901) Sou Hu Cai Jing·2025-08-26 13:54Core Viewpoint - The stock of Dabo Medical (002901) has shown a decline in price and significant net outflow of main funds, indicating potential concerns among investors [1][2]. Financial Performance - Dabo Medical reported a total revenue of 1.21 billion yuan for the first half of 2025, representing a year-on-year increase of 25.55% [3]. - The net profit attributable to shareholders was 244 million yuan, up 76.69% year-on-year [3]. - The second quarter of 2025 saw a single-quarter revenue of 660 million yuan, a 22.96% increase year-on-year, with a net profit of 141 million yuan, reflecting an 84.47% increase [3]. - The company has a gross margin of 71.01%, significantly higher than the industry average of 51.29% [3]. Market Position - Dabo Medical's total market capitalization is 23.955 billion yuan, ranking 10th in the medical device industry [3]. - The company has a price-to-earnings ratio (P/E) of 49.04, which is lower than the industry average of 66.21 [3]. - The return on equity (ROE) stands at 7.6%, placing it 8th in the industry [3]. Fund Flow Analysis - On August 26, 2025, the stock closed at 57.86 yuan, down 1.41%, with a turnover rate of 1.6% and a trading volume of 46,200 hands [1]. - The main funds experienced a net outflow of 26.8957 million yuan, accounting for 10.01% of the total trading volume [1][2]. - Retail investors saw a net inflow of 13.0377 million yuan, representing 4.85% of the total trading volume [1][2].